Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(1):191–197. doi: 10.1111/j.1476-5381.1995.tb16338.x

ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

J J Maguire 1, A P Davenport 1
PMCID: PMC1908752  PMID: 7647976

Abstract

1. We have characterized the constrictor endothelin receptors present in human isolated blood vessels using ETA and ETB selective agonists and antagonists. 2. Monophasic dose-response curves were obtained for ET-1 with EC50 values of 6.8 nM in coronary artery, 3.9 nM in internal mammary artery, 17.4 nM in pulmonary artery, 14.5 nM in aorta and 3.2 nM in saphenous vein. In coronary artery, ET-2 was equipotent with ET-1 with an EC50 value of 5.7 nM. The non-selective peptide, sarafotoxin 6b, was 2-3 times less potent than ET-1 but the maximum responses to these two were comparable. 3. In each vessel ET-3 was much less active than ET-1. No response was obtained to ET-3 in aorta and pulmonary artery or in up to 50% of coronary artery, mammary artery and saphenous vein preparations. In those preparations that did respond, dose-response curves were incomplete at 300 nM. Variable contractions were also obtained with the ETB-selective agonist, sarafotoxin 6c (S6c). Where responses were detected, although S6c was more potent than ET-1 (EC50 values of 0.6-1.2 nM), the maximum response produced was always less than 20% of that to ET-1. 4. The synthetic ETB agonists, BQ3020 and [1,3,11,15Ala]-ET-1, were without effect in any of the five blood vessels at concentrations up to 3 microM. 5. ET-1-induced vasoconstriction was blocked by the ETA-selective antagonists, BQ123 and FR139317.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
194

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  3. Bax W. A., Aghai Z., van Tricht C. L., Wassenaar C., Saxena P. R. Different endothelin receptors involved in endothelin-1- and sarafotoxin S6B-induced contractions of the human isolated coronary artery. Br J Pharmacol. 1994 Dec;113(4):1471–1479. doi: 10.1111/j.1476-5381.1994.tb17162.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bax W. A., Bos E., Saxena P. R. Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol. 1993 Aug 3;239(1-3):267–268. doi: 10.1016/0014-2999(93)91010-k. [DOI] [PubMed] [Google Scholar]
  5. Benigni A., Zoja C., Corna D., Orisio S., Longaretti L., Bertani T., Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993 Aug;44(2):440–444. doi: 10.1038/ki.1993.263. [DOI] [PubMed] [Google Scholar]
  6. Cacoub P., Dorent R., Maistre G., Nataf P., Carayon A., Piette C., Godeau P., Cabrol C., Gandjbakhch I. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol. 1993 Feb 15;71(5):448–450. doi: 10.1016/0002-9149(93)90452-i. [DOI] [PubMed] [Google Scholar]
  7. Chester A. H., O'Neil G. S., Allen S. P., Luu T. N., Tadjkarimi S., Yacoub M. H. Effect of endothelin on normal and diseased human coronary arteries. Eur J Clin Invest. 1992 Mar;22(3):210–213. doi: 10.1111/j.1365-2362.1992.tb01828.x. [DOI] [PubMed] [Google Scholar]
  8. Clozel M., Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 1993;52(9):825–834. doi: 10.1016/0024-3205(93)90081-d. [DOI] [PubMed] [Google Scholar]
  9. Costello K. B., Stewart D. J., Baffour R. Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. Eur J Pharmacol. 1990 Sep 21;186(2-3):311–314. doi: 10.1016/0014-2999(90)90450-k. [DOI] [PubMed] [Google Scholar]
  10. Cristol J. P., Warner T. D., Thiemermann C., Vane J. R. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davenport A. P., Maguire J. J. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994 Jan;15(1):9–11. doi: 10.1016/0165-6147(94)90120-1. [DOI] [PubMed] [Google Scholar]
  12. Davenport A. P., Nunez D. J., Hall J. A., Kaumann A. J., Brown M. J. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. doi: 10.1097/00005344-198900135-00045. [DOI] [PubMed] [Google Scholar]
  13. Davenport A. P., O'Reilly G., Kuc R. E. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 Mar;114(6):1110–1116. doi: 10.1111/j.1476-5381.1995.tb13322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Deray G., Carayon A., Le Hoang P. Increased endothelin level after cyclosporine therapy. Ann Intern Med. 1991 May 1;114(9):809–809. doi: 10.7326/0003-4819-114-9-809_1. [DOI] [PubMed] [Google Scholar]
  15. Fogo A., Hellings S. E., Inagami T., Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 1992 Sep;42(3):770–774. doi: 10.1038/ki.1992.346. [DOI] [PubMed] [Google Scholar]
  16. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. doi: 10.1111/j.1476-5381.1989.tb12038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fukuroda T., Kobayashi M., Ozaki S., Yano M., Miyauchi T., Onizuka M., Sugishita Y., Goto K., Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol (1985) 1994 May;76(5):1976–1982. doi: 10.1152/jappl.1994.76.5.1976. [DOI] [PubMed] [Google Scholar]
  18. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993 Nov;110(3):1201–1205. doi: 10.1111/j.1476-5381.1993.tb13942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Grossman E., Rosenthal T., Peleg E., Holmes C., Goldstein D. S. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993 Jul;22(1):22–26. doi: 10.1097/00005344-199307000-00004. [DOI] [PubMed] [Google Scholar]
  20. Grover G. J., Dzwonczyk S., Parham C. S. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993 Sep;27(9):1613–1618. doi: 10.1093/cvr/27.9.1613. [DOI] [PubMed] [Google Scholar]
  21. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hay D. W., Luttmann M. A., Hubbard W. C., Undem B. J. Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br J Pharmacol. 1993 Nov;110(3):1175–1183. doi: 10.1111/j.1476-5381.1993.tb13938.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Haynes W. G., Webb D. J. Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Lond) 1993 Apr;84(4):427–433. doi: 10.1042/cs0840427. [DOI] [PubMed] [Google Scholar]
  24. Hemsén A., Franco-Cereceda A., Matran R., Rudehill A., Lundberg J. M. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol. 1990 Dec 4;191(3):319–328. doi: 10.1016/0014-2999(90)94164-s. [DOI] [PubMed] [Google Scholar]
  25. Hughes A. D., Thom S. A., Woodall N., Schachter M., Hair W. M., Martin G. N., Sever P. S. Human vascular responses to endothelin-1: observations in vivo and in vitro. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S225–S228. [PubMed] [Google Scholar]
  26. Ihara M., Ishikawa K., Fukuroda T., Saeki T., Funabashi K., Fukami T., Suda H., Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20 (Suppl 12):S11–S14. doi: 10.1097/00005344-199204002-00005. [DOI] [PubMed] [Google Scholar]
  27. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Itoh S., Sasaki T., Ide K., Ishikawa K., Nishikibe M., Yano M. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun. 1993 Sep 15;195(2):969–975. doi: 10.1006/bbrc.1993.2139. [DOI] [PubMed] [Google Scholar]
  29. Karet F. E., Kuc R. E., Davenport A. P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993 Jul;44(1):36–42. doi: 10.1038/ki.1993.210. [DOI] [PubMed] [Google Scholar]
  30. Kiowski W., Linder L. Reversal of endothelin-1-induced vasoconstriction by nifedipine in human resistance vessels in vivo in healthy subjects. Am J Cardiol. 1992 Apr 15;69(12):1063–1066. doi: 10.1016/0002-9149(92)90864-u. [DOI] [PubMed] [Google Scholar]
  31. Liu J. J., Casley D., Wojta J., Gallicchio M., Dauer R., Johnston C. I., Buxton B. F. Effects of calcium- and ETA-receptor antagonists on endothelin-induced vasoconstriction and levels of endothelin in the human internal mammary artery. Clin Exp Pharmacol Physiol. 1994 Jan;21(1):49–57. doi: 10.1111/j.1440-1681.1994.tb02435.x. [DOI] [PubMed] [Google Scholar]
  32. Lüscher T. F., Yang Z., Tschudi M., von Segesser L., Stulz P., Boulanger C., Siebenmann R., Turina M., Bühler F. R. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990 Apr;66(4):1088–1094. doi: 10.1161/01.res.66.4.1088. [DOI] [PubMed] [Google Scholar]
  33. Maguire J. J., Bacon C. R., Fujimoto M., Davenport A. P. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994 Jun;12(6):675–680. [PubMed] [Google Scholar]
  34. Maguire J. J., Kuc R. E., O'Reilly G., Davenport A. P. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol. 1994 Sep;113(1):49–54. doi: 10.1111/j.1476-5381.1994.tb16172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McKay K. O., Black J. L., Diment L. M., Armour C. L. Functional and autoradiographic studies of endothelin-1 and endothelin-2 in human bronchi, pulmonary arteries, and airway parasympathetic ganglia. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S206–S209. doi: 10.1097/00005344-199100177-00059. [DOI] [PubMed] [Google Scholar]
  36. McNamara D. B., Light J. T., Minkes R. K., Saroyan R. M., Kvamme P., Rowe N., Webb W. R., Fox L., Kerstein M. D., Mills N. L. Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts. Mol Cell Biochem. 1992 Nov 4;117(1):81–85. doi: 10.1007/BF00230413. [DOI] [PubMed] [Google Scholar]
  37. Molenaar P., Kuc R. E., Davenport A. P. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol. 1992 Nov;107(3):637–639. doi: 10.1111/j.1476-5381.1992.tb14498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Okamura T., Matsumoto T., Ikemoto F., Toda N. Mechanisms of the biphasic responses to endothelin-3 in dog coronary arteries. Br J Pharmacol. 1992 Dec;107(4):1037–1041. doi: 10.1111/j.1476-5381.1992.tb13403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Papadopoulos S. M., Gilbert L. L., Webb R. C., D'Amato C. J. Characterization of contractile responses to endothelin in human cerebral arteries: implications for cerebral vasospasm. Neurosurgery. 1990 May;26(5):810–815. doi: 10.1097/00006123-199005000-00013. [DOI] [PubMed] [Google Scholar]
  40. Riezebos J., Watts I. S., Vallance P. J. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994 Feb;111(2):609–615. doi: 10.1111/j.1476-5381.1994.tb14780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Saetrum Opgaard O., Adner M., Gulbenkian S., Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994 Apr;23(4):576–583. doi: 10.1097/00005344-199404000-00009. [DOI] [PubMed] [Google Scholar]
  42. Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992 Mar;13(3):103–108. doi: 10.1016/0165-6147(92)90038-8. [DOI] [PubMed] [Google Scholar]
  43. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  44. Seo B., Oemar B. S., Siebenmann R., von Segesser L., Lüscher T. F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994 Mar;89(3):1203–1208. doi: 10.1161/01.cir.89.3.1203. [DOI] [PubMed] [Google Scholar]
  45. Sokolovsky M. Endothelins and sarafotoxins: receptor heterogeneity. Int J Biochem. 1994 Mar;26(3):335–340. doi: 10.1016/0020-711x(94)90053-1. [DOI] [PubMed] [Google Scholar]
  46. Sørensen S. S., Madsen J. K., Pedersen E. B. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol. 1994 Mar;266(3 Pt 2):F411–F418. doi: 10.1152/ajprenal.1994.266.3.F411. [DOI] [PubMed] [Google Scholar]
  47. Tomita K., Ujiie K., Nakanishi T., Tomura S., Matsuda O., Ando K., Shichiri M., Hirata Y., Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1989 Oct 19;321(16):1127–1127. doi: 10.1056/NEJM198910193211615. [DOI] [PubMed] [Google Scholar]
  48. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11- Cys15]-endothelin-1(11-21) FEBS Lett. 1994 Mar 28;342(1):103–103. doi: 10.1016/0014-5793(94)80593-8. [DOI] [PubMed] [Google Scholar]
  49. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21) FEBS Lett. 1992 Oct 12;311(1):12–16. doi: 10.1016/0014-5793(92)81355-p. [DOI] [PubMed] [Google Scholar]
  50. Wei C. M., Lerman A., Rodeheffer R. J., McGregor C. G., Brandt R. R., Wright S., Heublein D. M., Kao P. C., Edwards W. D., Burnett J. C., Jr Endothelin in human congestive heart failure. Circulation. 1994 Apr;89(4):1580–1586. doi: 10.1161/01.cir.89.4.1580. [DOI] [PubMed] [Google Scholar]
  51. White D. G., Garratt H., Mundin J. W., Sumner M. J., Vallance P. J., Watts I. S. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol. 1994 May 23;257(3):307–310. doi: 10.1016/0014-2999(94)90144-9. [DOI] [PubMed] [Google Scholar]
  52. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES